Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Tim A LabeurDavid W G Ten CateR Bart TakkenbergHicham AzahafMartijn G H van OijenOtto M van DeldenRobert A de ManJeroen L A van VugtJan Nicolaas Maria IJzermansFerry A L M EskensHeinz-Josef KlümpenPublished in: Acta oncologica (Stockholm, Sweden) (2018)
Landmark trial outcomes of sorafenib for HCC are reproducible in daily practice, provided that the SHARP eligibility criteria are respected. Based on the findings of this and previous studies, sorafenib usage should be restricted to Child-Pugh A patients.
Keyphrases